A Welcomed Primary Care Provider

doctors scope

The scheduling delay for a routine appointment with one of America’s 210,000 primary care doctors seems to be measured in weeks, even when the doctor’s practice is already the patient’s medical home.  New patient appointments often take six weeks.  For a good ophthalmologist, 2 or three months seems to be a normal wait.  Medical care […]

ACI in Forbes: FDA Action Can Save Lives, Money

drug vials

Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but the FDA needs to write the rules necessary to permit competitive entry. His piece is available to read and print at Forbes.

ACI in the Huffington Post: FDA Delays Will Cost Money and Lives

the-huffington

This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs.  These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics.  Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients.  The article calls on the FDA to accelerate its rulemaking and write […]

FDA’s Continued Delay Could Cost Lives

doctors scope

Just last week, Swiss drugmaker Novartis AG applied to create the first generic version of a brand named biologic drug for use in the United States. Their drug, a white blood cell stimulant, would be of great benefit to millions of cancer patients spending every last dime on incredibly expensive biologics.  Generic versions of name […]

ACI Asks FDA: Write Rules for Biosimilar Drug Market Entry

drug vials

July 10, 2014 Ms. Margaret A. Hamburg Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Dear Commissioner Hamburg: On behalf of The American Consumer Institute (ACI), a nonprofit educational and research organization, we are writing to raise an issue of critical concern regarding the naming of biosimilar drugs.  We […]

ACI Experts Write on the Health and Economic Effects of Counterfeit Drugs

drug vials

Today’s American Health & Drug Benefits (AH&DB) Journal, a peer-reviewed forum, published an article written by three ACI experts — Erwin A. Blackstone, Professor of Economics at Temple University; Joseph P. Fuhr, Jr., Professor of Economics at Widener University; and Steve Pociask, President of the American Consumer Institute, Center for Citizen Research.  The article can […]

ACI in Pittsburgh Gazette: PA’s Heavy Hand in Private Contracts

doctors scope

Imagine an instance where McDonald’s was mandated to purchase fries from Burger King – or GM was required to buy auto parts from Ford. Intuitively and economically, this does not make sense. Yet, that is exactly what the legislature is trying to do in Pennsylvania. The two parties in question though do not make fries […]

Physician Control over Electronic Health Records

doctors scope

Technical questions on how to build and store an electronic health record (EHR) are trivial compared with the more visceral issues of who should own it, what it should contain, and who can input into it.  By 2012, 70% of physicians had faced those questions, made tentative decisions, and taken on an EHR system. Today, […]

Affordable Care by the Numbers?

doctors scope

Although The Affordable Care Act became law in March 2010, its major impacts on the public are still being rescheduled.  While the individual mandate to obtain “adequate” healthcare coverage applies to adults and their family members starting in March 2014, employers’ obligation to offer that coverage has become a moveable feast.  Unfortunately “adequate” means whatever […]

Unaffordable Care Act: An Expensive Political Monument

government issues

The National Center for Health Statistics (NCHS) reported on January 28th 2014 that healthcare costs are a crushing burden on about a quarter of US families.  Perhaps the “1 in 4” quantification is the main value in the report, because acknowledging healthcare as a financial burden is too obvious. NCHS chose not to highlight the […]